Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26043642 | 0.80 | BIRC2 (0.35) | SCN1ASCN2ASCN3ACA14CA7 | |
| SCHEMBL25947214 | 0.79 | SCN1A (0.33) | SCN1ASCN2ASCN3ACA12CA14 | |
| SCHEMBL25947159 | 0.76 | MMP8 (0.35) | SCN1ASCN2ASCN3A | |
| SCHEMBL26418495 | 0.74 | MEN1 (0.34) | — | |
| SCHEMBL17212387 | 0.72 | SMN1; SMN2 (0.35) | CA12CA14CA7CA9 | |
| SCHEMBL14154237 | 0.72 | CA12 (0.31) | CA12CA14 | |
| SCHEMBL7223762 | 0.71 | CA1 (0.43) | CA12CA9 | |
| SCHEMBL7222777 | 0.71 | HCAR2 (0.38) | — | |
| SCHEMBL17365966 | 0.71 | TSHR (0.37) | — | |
| SCHEMBL14790215 | 0.71 | MAPK1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250056-A1 | PROCESS FOR SYNTHESIZING LIPIDS | BRISTOL-MYERS SQUIBB COMPANY | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250056-A1 | PROCESS FOR SYNTHESIZING LIPIDS | PLIN1, SREBF1, SREBF2 | SCN1A 4087/4885SCN2A 4241/4885SCN3A 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.